Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

HIV Drug Efavirenz Inhibits CYP21A2 Activity with Possible Clinical Implications

J. Malikova, T. Zingg, R. Fingerhut, S. Sluka, M. Grössl, S. Brixius-Anderko, R. Bernhardt, J. McDougall, AV. Pandey, CE. Flück,

. 2019 ; 91 (4) : 262-270. [pub] 20190628

Jazyk angličtina Země Švýcarsko

Typ dokumentu kazuistiky, časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc20006200

BACKGROUND: The HIV drugs lopinavir and ritonavir have recently been reported to cause transient adrenal insufficiency in preterm newborns. We, therefore, considered HIV drugs as a cause of transiently elevated 17-hydroxyprogesterone (17OHP) levels in a neonatal screening test for congenital adrenal hyperplasia in a preterm girl exposed to zidovudine, efavirenz, tenofovir, and emtricitabine. OBJECTIVE: So far, HIV drugs have not been tested for their effect on steroidogenesis and the steroidogenic enzyme activity of CYP21A2 specifically in an in vitro system. METHODS: We tested the effect of efavirenz, tenofovir, emtricitabine, and zidovudine on steroidogenesis of human adrenal H295R cells. Cells were treated with the drugs at different concentrations including concentrations in therapeutic use. The effect on CYP21A2 activity was assessed by testing the conversion of radiolabeled 17OHP to 11-deoxycortisol. Cell viability was tested by an MTT assay. In addition, recombinant human CYP21A2 protein was used to assess direct drug effects on CYP21A2 activity. RESULTS: We observed significantly decreased CYP21A2 activity in both in vitro testing systems after treatment with efavirenz at therapeutic concentrations. Moreover, efavirenz affected cell viability. By contrast, the other test drugs did not affect steroidogenesis. Follow-up of our patient revealed elevated 17OHP and androgen levels during the first weeks of life, but values normalized spontaneously. Genetic testing for CYP21A2 mutations was negative. Thus, it remains unsettled whether the transient 17OHP elevation in this baby was due to a drug effect. CONCLUSION: The HIV drug efavirenz inhibits CYP21A2 activity in vitro through direct interaction with enzyme catalysis at therapeutic concentrations. This may have clinical implications for HIV treatment in children and adults. However, so far, clinical data are scarce, and further studies are needed to be able to draw clinical conclusions.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc20006200
003      
CZ-PrNML
005      
20230712142449.0
007      
ta
008      
200511s2019 sz f 000 0|eng||
009      
AR
024    7_
$a 10.1159/000500522 $2 doi
035    __
$a (PubMed)31256164
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sz
100    1_
$a Křenek Malíková, Jana $u Division of Pediatric Endocrinology and Diabetology, Department of Pediatrics, Inselspital, University Hospital of Bern, University of Bern, Bern, Switzerland. Department of BioMedical Research, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland. Department of Pediatrics, University Hospital Motol, SecondFaculty of Medicine, Charles University in Prague, Prague, Czechia. $7 xx0158263
245    10
$a HIV Drug Efavirenz Inhibits CYP21A2 Activity with Possible Clinical Implications / $c J. Malikova, T. Zingg, R. Fingerhut, S. Sluka, M. Grössl, S. Brixius-Anderko, R. Bernhardt, J. McDougall, AV. Pandey, CE. Flück,
520    9_
$a BACKGROUND: The HIV drugs lopinavir and ritonavir have recently been reported to cause transient adrenal insufficiency in preterm newborns. We, therefore, considered HIV drugs as a cause of transiently elevated 17-hydroxyprogesterone (17OHP) levels in a neonatal screening test for congenital adrenal hyperplasia in a preterm girl exposed to zidovudine, efavirenz, tenofovir, and emtricitabine. OBJECTIVE: So far, HIV drugs have not been tested for their effect on steroidogenesis and the steroidogenic enzyme activity of CYP21A2 specifically in an in vitro system. METHODS: We tested the effect of efavirenz, tenofovir, emtricitabine, and zidovudine on steroidogenesis of human adrenal H295R cells. Cells were treated with the drugs at different concentrations including concentrations in therapeutic use. The effect on CYP21A2 activity was assessed by testing the conversion of radiolabeled 17OHP to 11-deoxycortisol. Cell viability was tested by an MTT assay. In addition, recombinant human CYP21A2 protein was used to assess direct drug effects on CYP21A2 activity. RESULTS: We observed significantly decreased CYP21A2 activity in both in vitro testing systems after treatment with efavirenz at therapeutic concentrations. Moreover, efavirenz affected cell viability. By contrast, the other test drugs did not affect steroidogenesis. Follow-up of our patient revealed elevated 17OHP and androgen levels during the first weeks of life, but values normalized spontaneously. Genetic testing for CYP21A2 mutations was negative. Thus, it remains unsettled whether the transient 17OHP elevation in this baby was due to a drug effect. CONCLUSION: The HIV drug efavirenz inhibits CYP21A2 activity in vitro through direct interaction with enzyme catalysis at therapeutic concentrations. This may have clinical implications for HIV treatment in children and adults. However, so far, clinical data are scarce, and further studies are needed to be able to draw clinical conclusions.
650    12
$a kongenitální adrenální hyperplazie $x chemicky indukované $x enzymologie $7 D000312
650    _2
$a dospělí $7 D000328
650    12
$a benzoxaziny $x aplikace a dávkování $x škodlivé účinky $7 D048588
650    _2
$a buněčné linie $7 D002460
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a HIV infekce $x farmakoterapie $7 D015658
650    _2
$a lidé $7 D006801
650    _2
$a novorozenec $7 D007231
650    _2
$a těhotenství $7 D011247
650    _2
$a infekční komplikace v těhotenství $x farmakoterapie $7 D011251
650    12
$a předčasný porod $x chemicky indukované $x enzymologie $7 D047928
650    12
$a zpožděný efekt prenatální expozice $x chemicky indukované $x enzymologie $7 D011297
650    12
$a inhibitory reverzní transkriptasy $x aplikace a dávkování $x škodlivé účinky $7 D018894
650    _2
$a steroid-21-hydroxylasa $x antagonisté a inhibitory $x metabolismus $7 D013255
655    _2
$a kazuistiky $7 D002363
655    _2
$a časopisecké články $7 D016428
700    1_
$a Zingg, Tanja $u Division of Pediatric Endocrinology and Diabetology, Department of Pediatrics, Inselspital, University Hospital of Bern, University of Bern, Bern, Switzerland.
700    1_
$a Fingerhut, Ralph $u Swiss Newborn Screening Laboratory, Children's Research Center (CRC), University Children's Hospital of Zurich, Zurich, Switzerland.
700    1_
$a Sluka, Susanna $u Swiss Newborn Screening Laboratory, Children's Research Center (CRC), University Children's Hospital of Zurich, Zurich, Switzerland.
700    1_
$a Grössl, Michael $u Department of Nephrology and Hypertension, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.
700    1_
$a Brixius-Anderko, Simone $u Department of Biochemistry, Faculty of Technical and Natural Sciences, Saarland University, Saarbrücken, Germany.
700    1_
$a Bernhardt, Rita $u Department of Biochemistry, Faculty of Technical and Natural Sciences, Saarland University, Saarbrücken, Germany.
700    1_
$a McDougall, Jane $u Division of Neonatology, Department of Pediatrics, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.
700    1_
$a Pandey, Amit V $u Division of Pediatric Endocrinology and Diabetology, Department of Pediatrics, Inselspital, University Hospital of Bern, University of Bern, Bern, Switzerland. Department of BioMedical Research, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.
700    1_
$a Flück, Christa E $u Division of Pediatric Endocrinology and Diabetology, Department of Pediatrics, Inselspital, University Hospital of Bern, University of Bern, Bern, Switzerland, christa.flueck@dbmr.unibe.ch. Department of BioMedical Research, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland, christa.flueck@dbmr.unibe.ch.
773    0_
$w MED00175757 $t Hormone research in paediatrics $x 1663-2826 $g Roč. 91, č. 4 (2019), s. 262-270
856    41
$u https://pubmed.ncbi.nlm.nih.gov/31256164 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20200511 $b ABA008
991    __
$a 20230712142451 $b ABA008
999    __
$a ok $b bmc $g 1525058 $s 1096256
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2019 $b 91 $c 4 $d 262-270 $e 20190628 $i 1663-2826 $m Hormone research in paediatrics $n Horm Res Paediatr $x MED00175757
LZP    __
$a Pubmed-20200511

Najít záznam

Citační ukazatele

Nahrávání dat ...

Možnosti archivace

Nahrávání dat ...